tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Florio G et al. | The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. | 2000 | AIDS | pmid:10853974 |
| Nowak P et al. | Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. | 2003 | AIDS Res. Hum. Retroviruses | pmid:12581512 |
| Sklar EM | Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? | 2006 | AJNR Am J Neuroradiol | pmid:16971594 |
| Bargalló N et al. | Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. | 2000 | AJNR Am J Neuroradiol | pmid:10730638 |
| Bartynski WS et al. | Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. | 2001 Nov-Dec | AJNR Am J Neuroradiol | pmid:11733324 |
| Bartynski WS et al. | Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. | 2004 | AJNR Am J Neuroradiol | pmid:14970028 |
| Bartynski WS et al. | Posterior reversible encephalopathy syndrome after solid organ transplantation. | 2008 | AJNR Am J Neuroradiol | pmid:18272559 |
| Schuuring J et al. | Severe tacrolimus leukoencephalopathy after liver transplantation. | 2003 Nov-Dec | AJNR Am J Neuroradiol | pmid:14625238 |
| Oliverio PJ et al. | Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. | 2000 | AJNR Am J Neuroradiol | pmid:10954277 |
| Appignani BA et al. | Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. | 1996 | AJR Am J Roentgenol | pmid:8623651 |
| Srinivas NR | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589592 |
| BenÃtez C et al. | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589580 |
| Ierardi E et al. | Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207512 |
| O'Leary JG | Editorial: tacrolimus-how low can you go? | 2017 | Aliment. Pharmacol. Ther. | pmid:28589579 |
| Firpi RJ et al. | Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113371 |
| Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
| Solari S et al. | Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. | 2017 | Aliment. Pharmacol. Ther. | pmid:28261844 |
| Hisanaga Y et al. | Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971291 |
| Hoshino H et al. | Effects of FK506 on an experimental model of colitis in rats. | 1995 | Aliment. Pharmacol. Ther. | pmid:7544633 |
| Taylor KM and Sparrow MP | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040166 |